UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1317, 2025

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

Delaware	001-38325	33-0936180
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

70 Doppler

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

(949) 261-2900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		NVNO		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0103. ~~Regulation~~Amendments FDto ~~Disclosure~~Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 1317, 2025, the Board of Directors of enVVeno Medical Corporation (“we,” “us,” “our,” or the “Company”) ~~issued~~ aapproved ~~press~~an ~~release~~amendment ~~announcing~~to the Company’s ~~had~~Amended ~~received~~and anRestated ~~unfavorable~~Bylaws. ~~appeal~~The ~~decision~~amendment ~~from~~revises Section 1.5 to modify the Uquorum requirement for meetings of stockholders.S As amended, Section 1.5 ~~Food~~provides &that, ~~Drug~~except ~~Administration in~~as ~~response~~otherwise torequired ~~its~~by ~~Premarket~~applicable law, ~~Approval~~the ~~application~~certificate ~~for~~of ~~VenoValve®~~incorporation or the bylaws, athe ~~surgical~~presence ~~replacement~~in ~~venous~~person ~~valve~~or ~~for~~by ~~treating~~proxy ~~severe~~of ~~deep~~holders ~~chronic~~of thirty-three and one-third percent ~~venous~~in ~~insufficiency.~~voting ~~The~~power ~~press~~of ~~release~~the isoutstanding ~~being~~shares ~~furnished~~entitled asto ~~Exhibit~~vote 99at the meeting shall constitute a quorum.1 The amendment to ~~this~~Section ~~report~~1.5 became effective immediately upon approval by the Board.

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our clinical trials, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Current Report.

Item 9.01 Financial Statements and Exhibits.

Set forth below is a list of Exhibits included as part of this Current Report:

Exhibit No.		Description
99.1		Press Release
3.1		Amended and Restated Bylaws of enVVeno Medical Corporation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVVENO MEDICAL CORPORATION
Dated: November 13, 2025	/s/ Robert A. Berman
Dated: November 20, 2025	/s/ Robert A. Berman
	Robert A. Berman
	Chief Executive Officer

Filing Compare · enVVeno Medical Corp